Fabry Disease Treatment Market: Recent Industry Trends, Analysis and Forecast 2030

Fabry Disease Treatment Market Overview:

In a recent research report by Market Research Community, the Fabry disease treatment market is expected to surpass USD 5.03 Billion by the year 2030, from USD 2.10 Billion in 2021.

The Fabry disease runs in families. Numerous symptoms, such as pain in the hands and feet and a particular rash, are possible. The symptoms of the diseases include Cloudy vision, hearing loss, ringing in the ears, Sweating less than normal, and others. Two common treatments used in the diagnosis of the disease include enzyme replacement therapy (ERT), and oral medication migalastat.

Top Key Players of the:

Shire Plc., Sanofi S.A., Amicus Therapeutics Inc., JCR Pharmaceuticals Co Ltd., ISU Abxis Co Ltd., Idorsia Pharmaceuticals Ltd., Avrobio Inc., Protalix Biotherapeutics Inc., Moderna Therapeutics Inc., and Greenovation Biotech GmbH.

On the Basis of Treatment:
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)

Regional Analysis:
North America–
(U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)

In 2021, the market sector for enzyme replacement therapy had the major market share. By 2030, it is anticipated continue its position in the Fabry disease treatment market. The dominance of the market is being supported by robust sales of Fabrazyme and Replagal as well as prospective approval of strong pipeline prospects. However, a notable rise in patient benefits will require the introduction of new effective therapeutic options, such as gene therapies.

The Asia Pacific offers huge growth potential for pharmaceutical companies due to rising healthcare costs and expanding infrastructure. Moreover, Latin America and the area are both expected to grow at the quickest rates during the forecast period, partly because growing countries in the region have huge populations.

The Fabry disease treatment market is projected to grow at a significant pace reaching a CAGR of approximately 10.2%, over the forecast period of 2022–2030, despite a considerable fall in Treatment sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.

The study is consolidated into major segments and further into sub-segments, such as by Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others) to forecast the Fabry disease treatment market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.

The research provides answers to the following key questions:

  • What is the expected growth rate of the Fabry Disease Treatment Market? What will be the market size for the forecast period, 2022 – 2030?
  • What are the major driving forces responsible for transforming the trajectory of the industry?
  • Who are major vendors dominating the Fabry Disease Treatment industry across different regions? What are their winning strategies to stay ahead in the competition?
  • What are the market trends business owners can rely upon in the coming years?
  • What are the threats and challenges expected to restrict the progress of the industry across different countries?
  • What are the key opportunities that business owners can bank on for the forecast period, 2022 – 2030?

Our Recently Published Reports

Market Research Community


Comments are closed